ResearchGate Impact Factor (2018): 0.28 | SJIF (2019): 7.583

# Effectiveness of Balapanchamrita Yoga and Panchakarma based Procedures in the Management of Children with Cerebral Palsy; A Single Arm Prospective Clinical Trial

Upasana Sonker<sup>1</sup>, Mahapatra Arun Kumar<sup>2</sup>, Rajagopala S.<sup>3</sup>

PG Scholar, Assistant Professor, Associated Professor, Dept. of Kaumarabhritya, All India Institute of Ayurveda, New Delhi, India

Abstract: Cerebral palsy is one of the most serious disease in developing child that's occur due to insult of developing brain during pregnancy, at the time of delivery and after the birth of child up to 2 years of age. The world-wide incidence of cerebral palsy is 2.5/1000 live births and 3/1000 live births in India. CP is manifested as developmental delay, movement disorder, visual disability, hearing disability, in-coordination of speech and involvement of cognitive function with or without seizures. The symptoms of CP are showing the similarity with some Ayurvedic diseases such as Vatavyadhi, Phakka, Ekanga Roga, Sarvanga Roga, Pakshaghata, Janampravrita Dosha and Dauhridya-avamanana etc., In present scenario, any medical science and pathies are not give the complete remission or cure of CP. But Ayurvedic Panchakarma procedures show the satisfactory result in the management of CP. So that 15 patient of cerebral palsy were treated with three course of treatment (each course consist of 3 days Udvartana, 14 days Sarvanga Abhyanga with Ksheerabala taila and Nadi Swedana with Eranda patra kwatha and 7 days of Matra Basti with Ksheerabala taila from 8th days of Sarvanga Abhyanga and Nadi Swedana) with an interval of 14 days along with internal medication of Balapanchamrita Yoga with the aim to reduce the spasticity, improvement in range of motion of joints and quality of life of CP Child. The total 81 days treatment were shown the significant result in the management of Cerebral palsy.

Keywords: Cerebral palsy, Neuromotor disorder, Vatavyadhi, Matra Basti

## 1. Introduction

Population based studies from around the world reported prevalence of cerebral palsy ranging from 1.5-4 per 1000 live births [1]. Cerebral palsy is characterised by persistent primitive reflexes, abnormal muscle tone, or motor development and coordination; and also associated with secondary co-morbidities like 28% cases having vision problems, 23-56% cases having learning disabilities [2]; and also 31% to 88% cases having dysarthria [3]. Spastic diplegic CP is characterized by normal cognition because the lesion is in the periventricular white matter, i.e. sparing the cortical grey matter. While in spastic quadriplegic CP have greater degree of mental retardation than children with spastic hemiplegia. The spasticity and movement disorders are the core symptoms of CP, difficulties with thinking, learning, feeling, communication and behaviour often co-occur. The treatment were plan as per the condition of patient, severity of disease and associated complications- Physical therapy, Occupational therapy, Speech therapy, Medication(antcholinergic drugs etc) and advanced management includes Autologous stem cell activation treatment in order to expand the blood vessels and nourish the neurons, stem cell transplantation procedure, Botulinum toxin type A injection, Selective dorsal rhizotomy (SDR), Orthotic devices such as ankle-foot orthoses (AFOs), Hyperbaric oxygen therapy (HBOT), Neuroplasticity, cord blood therapy, Hippotherapy, conductive education and Recreational therapy are the newer advancements under trial in the management of CP. Vitiated Vata Dosha is responsible for the symtomps of cerebral palsy. So Vata pacify measures play important role in the management of CP. Treatment of Vata Dosha consists of a variety of treatment modalities including Snehana, Swedana, Basti etc Panchkarma procedures. It improves gross as well as fine motor functions, provides nourishment, improves overall general condition and quality of life in children with CP. As per preventive aspect and the management in CP, there are no satisfactory criteria developed till date for the complete cure.

**Aim and Objective:** To assess the effect of Panchakarma procedure with oral administration of *Balapanchamrita Yoga* in Spasticity and Range of motion/movement in CP Child.

#### 2. Material & Method

The study was conducted on 15 clinically diagnosed and confirmed patients of Cerebral palsy from OPD/IPD, department of kaumarabhritya AIIA, New Delhi.

#### A. Inclusion criteria

- Diagnosed case of Cerebral palsy and age between 1-12 years of either sex.
- Parents submitting written consent to participate in the study.

#### B. Exclusion criteria

- Progressive neurological disorder, severe intractable epilepsy as co-morbidity, congenital disorders/anomalies.
- Children had received Botox (last 1yr) or had undergone Phenol block injection or intrathecal Baclofen medication, Recent orthopedic surgery/casting/splint and Fixed contractures.
- Caregiver not willing to sign the informed consent form.

Volume 9 Issue 10, October 2020

www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

Paper ID: SR201007190124 DOI: 10.21275/SR201007190124 889

ResearchGate Impact Factor (2018): 0.28 | SJIF (2019): 7.583

#### C. Criteria of Assessments

- Modified Ashworth Scale [4]
- Gross Motor Functional Manual Scale [5]
- Quality of Life [6]

#### **D.** Treatment Protocol

A total 81 days of treatment was given to the patient in the form of three courses with interval of 15 days between each course of treatment.

- Udwartana: 3days with Tilapinyaka churna for 15-20 min.
- Sarvanga Abhyanga: 14 days with Ksheerabala taila for 20 min.
- Nadi Swedana: 14 days with Eranda patra kwath.
- Matra Basti: 7 days with Ksheerabala taila (start from 8<sup>th</sup> day of Sarvanga Abhyanga and Nadi Swedana).

Internal medication: Balapanchamrita Yoga [7]

- Ingredients: Haritaki (Terminalia chebula Retz.), Pippali (Piper longum Linn.), Shunthi (Zingiber officiale Rosc.), Misreya (Foenieculum vulgate Mill.) and Hingu (Ferula narthex Boiss.).
- Dosage form- Churna
- Anupana- Madhu
- Dose & Duration Dose as per age of child for 81 days **Dosage:**[Adult dose\*Age of child (in years)

12+Age in years

• <u>Time of Administration</u>- Twice a day, Morning and Evening.

Institutional Ethical Clearance (IEC) and Clinical Trial Registry of India (CTRI) were done before initiating the clinical study [IEC Number: AIIA/2018/PG-98; CTRI Registration number: CTRI/2019/06/019645, trial registered prospectively]

Table 1.1: Showing Total duration and course of the clinical study

Course	Udwartana	Sarvanga Abhyanga & Nadi Swedana	Matra Basti	Total			
Ist	3 days with Tilapinyaka churna	14 days with Ksheerabala taila And Eranda patra kwatha	7 days with Ksheerabala taila	17 days			
	GAP						
2 <sup>nd</sup>	3 days with Tilapinyaka churna	14 days with <i>Ksheerabala taila</i> And <i>Eranda patra kwatha</i>	7 days with Ksheerabala taila	17 days			
GAP							
3 <sup>rd</sup>	3 days with Tilapinyaka churna	14 days with <i>Ksheerabala taila</i> And <i>Eranda patra kwatha</i>	7 days with Ksheerabala taila	17 days			
Total	81 days Panchakarma procedure with Balapanchamrita Yoga orally						

#### 3. Observation and Results

In the present study, the total 15 patient were registered and completed the 3 course of treatment. An equal number of patients i.e., 73.33% were from age group of 6-12 years. The majority of patients were male [60%] and 93.33% of total patients presented with history of delayed cry. Further, Meconium aspiration was reported in 26.67% cases, seizures in 13.33% and Jaundice in 26.67% cases. 80% of the total

patients required hospitalization and 66.67% patients were needed resuscitation. 40% of the total patients were not achieved bowel and 46.67% not achieved bladder control. 86.67% patients presented with spastic type of CP, 06.67% Dyskinetic and 06.67% mixed CP. Among the Spastic CP, 53.33% patients were of Spastic diplegic CP and 46.67% patients Spastic quadriplegic CP. 86.67% patients had speech problems and problems with eyes and vision were seen in 20% patients.

**Table 1.2:** Showing effect of therapy on GMFM Scale (N=15)

Assassment peremeters	Mean score		Mean	SD +/-	C E.	D£	т	P value
Assessment parameters	BT	AT	(BT-AT)	SD +/-	S.EI.	DI	1	r value
Lying & Rolling	59.42	89.53	30.11	25.89	6.68	14	4.50	< 0.000
Sitting	48.55	74.77	27.22	17.06	4.40	14	6.18	< 0.000
Crawling & Kneeling	27.98	51.11	23.17	14.99	3.87	14	5.98	< 0.000
Standing	12.1	37.77	25.66	16.16	4.17	14	6.15	< 0.000
Walking & Running	10	28.33	18.33	16.07	4.15	14	4.41	< 0.001

**Table 1.3:** Showing effect of therapy on QOL Scale(N=15)

Tuble Ties showing effect of therapy on QUI beare(1, 12)									
Assessment parameters	Mean BT	score AT	Mean (BT-AT)	SD +/-	S.Er.	Df	T	P value	
			` /						
Family & Friends	65.38	74.12	8.73	3.67	0.94	14	9.19	< 0.000	
Participation	30.92	37.96	7.03	5.23	1.35	14	5.20	< 0.000	
Communication	55.3	64.19	8.88	6.23	1.60	14	5.52	< 0.000	
Health	51.89	61.66	9.76	2.96	0.76	14	12.7	< 0.000	
Special equipment	52.58	61.47	8.88	10.45	2.70	14	3.29	< 0.005	
Pain & Bother	72.91	58.33	14.58	5.98	1.54	14	9.43	< 0.000	
Final question	61.62	51.55	10.07	2.03	0.52	14	19.18	< 0.000	
Access	57.28	65.67	8.39	3.76	0.97	14	8.64	< 0.000	
Your health	80.88	86.21	5.33	3.54	0.91	14	5.82	< 0.000	

Volume 9 Issue 10, October 2020

www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

Paper ID: SR201007190124 DOI: 10.21275/SR201007190124 890

ResearchGate Impact Factor (2018): 0.28 | SJIF (2019): 7.583

Table showing 1.4 Effect of therapy on MAS (N=15)

A	Mean score			CD /	S.Er.	Df	Т	P value
Assessment parameters	BT	AT	Mean (BT-AT)	SD +/-	S.Er.	וט	1	P value
Elbow Rt.	2.1	1.1	1.00	0.53	0.13	14	7.24	< 0.000
Elbow Lt.	2.1	1.1	1.00	0.53	0.13	14	7.24	< 0.000
Wrist	2.06	1.13	0.93	0.49	0.12	14	7.29	< 0.000
Fingers	2.06	1.13	0.93	0.49	0.12	14	7.29	< 0.000
Thumb	2.06	1.13	0.93	0.49	0.12	14	7.29	< 0.000
Hamstring Rt.	2.96	1.63	1.33	0.48	0.12	14	10.58	< 0.000
Hamstring Lt.	2.96	1.63	1.33	0.48	0.12	14	10.58	< 0.000
Quadriceps Rt.	2.96	1.63	1.33	0.48	0.12	14	10.58	< 0.000
Quadriceps Rt.	2.96	1.63	1.33	0.48	0.12	14	10.58	< 0.000
Gastrocnemius	2.96	1.63	1.33	0.48	0.12	14	10.58	< 0.000
Soleus	2.96	1.63	1.33	0.48	0.12	14	10.58	< 0.000

**Table 1.5:** Showing Overall response of the therapy

Parameters		IAS	<b>GMFM</b>		QOL	
		%	No.	%	No.	%
No response (Less than 5%)	0	0	0	0	0	0
Mild response –I (5%-25%)	7	46.67	9	60	15	100
Mild response –II (25%-50%)	8	53.33	6	40	0	0
Moderate response (50%-75%)	0	0	0	0	0	0
Excellent response (75%-100%)	0	0	0	0	0	0


**Table 1.6:** Showing Overall Clinical improvement of the therapy

S.No.	Parameter	Improvement		
		(In %)		
1.	MAS (Modified Ashworth Scale)	23.67		
2.	GMFM (Gross Motor Function Manual Scale)	28.54		
3.	QOL (Quality of life)	09.15		

## 4. Discussion

Spasticity is the one of the most important reason for orthopaedic disability in CP Child. After a long period, spasticity gets to convert the bone contracture. Unfortunately, the complete cure of disease in any medical science till date is not available. As per the symptoms of cerebral palsy, it can be compare with some condition in Ayurvedic texts such as Vata predominant state. So the Ayurvedic management of cerebral palsy is mainly target on Vata Dosha. In this present study Udwartana seems to be beneficial effect in reducing the spasticity in CP child and it is a prime procedure in 'Amavastha' (collected waste product inside the body) or 'Kapha Dosha Aadhikyaavastha, [8]. Udwartana with finely grinded powder of Tilapinyaka churna clear orifices of hair follicles, improves lymphatic circulation and improves Transdermal Drug Delivery (TDD). Thus Udwartana is helpful to mobilized absorbed drug potency to the target site by increased circulation. Abhyanga directly works on Vata to bring it back to normalcy. When vata comes to normalcy development of milestones will become normal [9]. Abhyanga stimulate sensory nerve ending of the skin and gives abundant sensory inputs to the cortical and different parts of the brain. And also reduces muscle tone, improves muscle bulk and power in CP child [10]. A study reported that in hemiparetic subjects the H-reflex was depressed during both continuous and intermittent tendon pressure. Intermittent pressure is found more effective than continuous pressure. Swedana relives heaviness, stiffness and coldness in the body parts [11]. *Ksheerabala Taila* has a Vatahara property and help in the alleviation of vitiated

Vata Dosha. Basti not only helps in expelling the vitiated dosha's from the pakwashaya but also helps in taking control over the vitiated Vata, and operates the functions of the whole body from Pakwashaya. Thus the Basti treatment gains much important in the management of Vata. In this study, 46.67% patients has shown mild response I and 53.33% patients with mild response II on Modified Ashworth scale. 60% patients have show mild response I and 40% patients with mild response II on Gross Motor Function Manual Scale. 100% patients have shown mild response I on Quality of life scale.



#### 5. Conclusion

The overall comparative clinical improvement in the present study have shown 23.67% on Modified Ashworth scale, 28.54% on Gross Motor Function Manual Scale, 9.15% on Quality of life scale. The improvement in condition of CP patients is occurring due to combined approach of *Udawartana, Abhyanga, Nadi Swedana* and *Matra Basti*. All procedures play an important role in the management of CP and also provide the plate form for next procedures to do better in every step. Thus the Panchakarma procedure shows the significant effect in the management of CP.

#### References

- [1] Data and statistics/Cerebral palsy/NCBDDD/CDC. www.cdc.gov Retrieved on 3/09/20.
- [2] Kent R (2013). "Chapter 38: Cerebral Palsy". In Barnes MP, Good DC (eds.). Handbook of Clinical Neurology. 3.110. Elsevier.pp.443-459. ISBN 978-0444529015.
- [3] Hirsh Adam T.; Gallegos Jaun C.; Gertz Kevin J.; Engel Joyce M.; Jensen Mark P. (2010). "Symptoms Burden

## Volume 9 Issue 10, October 2020

www.ijsr.net

<u>Licensed Under Creative Commons Attribution CC BY</u>

Paper ID: SR201007190124 DOI: 10.21275/SR201007190124 891

ResearchGate Impact Factor (2018): 0.28 | SJIF (2019): 7.583

- in Individuals with Cerebral Palsy" Journal of Rehabilitation Research & Development. 47(9):863-67. Doi:10.1682/jrrd.2010.03.0024, PMC 3158699. PMID 21174251
- [4] www.rehabmeasures.org; assess on 2019
- [5] http://motorgrowth.canchild.ca/en/GMFCS/resources/G MFCS-ER.pdf; assess on 2019
- [6] V2.1 CPQOL primary caregiver.pdf; assess on 2019
- [7] Vaghbhatacharya, Rasaratna Samuchchaya, Surattnojjvala hindi Commentary by Kaviraj Sri Ambikadatta Sastri, chapter 22, Chaukhamba Amarabharti Prakashan, Varanasi., page no. 517.
- [8] Mamidi P, Gupta K, Ayurvedic management of cerebral palsy: Report of two cases with review of literature. *Int Res J Pharm.*2015;6(1):73-76.
- [9] Bhinde SM, Patel KS, Kori VK, et al. Management of spastic cerebral palsy through multiple Ayurveda treatment modalities. AYU.2014;35(4):462-466.
- [10] Rathia S, Kori VK, Rajagopala S, et al. A clinical study to assess the effect of Samvardhana ghrita and yoga basti in cerebral palsy, Pharma Science Monitor. 2015;6(4):108-117.
- [11] Vyas AG, Kori VK, Rajagopala S, et al. Etiopathological study on cerebral palsy and its management by Shashtika Shali Pinda Sweda and Samvardhana Ghrita. AYU.2013;34(1):56-62.

Volume 9 Issue 10, October 2020 www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

892

Paper ID: SR201007190124 DOI: 10.21275/SR201007190124